Zobrazeno 1 - 10
of 102
pro vyhledávání: '"Koji Haratani"'
Autor:
Takehiro Uemura, Hirotsugu Kenmotsu, Daisuke Hazama, Shunsuke Teraoka, Hiroshi Kobe, Koichi Azuma, Teppei Yamaguchi, Takeshi Masuda, Toshihide Yokoyama, Kohei Otsubo, Koji Haratani, Daisuke Hayakawa, Masahide Oki, Shinnosuke Takemoto, Tomohiro Ozaki, Yusaku Akashi, Akito Hata, Hiroya Hashimoto, Nobuyuki Yamamoto, Kazuhiko Nakagawa
Publikováno v:
Cancer Medicine, Vol 12, Iss 23, Pp 21097-21110 (2023)
Abstract Background Actionable tumor genomic alterations, primarily EGFR mutations, occur in nearly 70% of Japanese advanced nonsquamous non‐small cell lung cancer (NSCLC) patients. Standard assessment of tumor tissue includes rapid testing for EGF
Externí odkaz:
https://doaj.org/article/653a72701e5d487b855668fed38c1519
Autor:
Takeshi Masuda, Satoru Miura, Yuki Sato, Motoko Tachihara, Akihiro Bessho, Atsushi Nakamura, Taichi Miyawaki, Kohei Yoshimine, Masahide Mori, Hideaki Shiraishi, Kosuke Hamai, Koji Haratani, Sumiko Maeda, Eriko Tabata, Chiyoe Kitagawa, Junko Tanizaki, Takumi Imai, Shohei Nogami, Nobuyuki Yamamoto, Kazuhiko Nakagawa, Noboru Hattori
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-11 (2023)
Abstract Small amounts of epidermal growth factor receptor (EGFR) T790M mutation (micro-T790M), which is detected using droplet digital PCR (ddPCR) but not conventional PCR, in formalin-fixed and paraffin-embedded (FFPE) samples have been investigate
Externí odkaz:
https://doaj.org/article/e8bde43f8c7f40679382597541262079
Autor:
Taichi Miyawaki, Hirotsugu Kenmotsu, Hideyuki Harada, Yasuhisa Ohde, Yasutaka Chiba, Koji Haratani, Tamio Okimoto, Tomohiro Sakamoto, Kazushige Wakuda, Kentaro Ito, Takehiro Uemura, Shinya Sakata, Yoshihito Kogure, Yasumasa Nishimura, Kazuhiko Nakagawa, Nobuyuki Yamamoto
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-6 (2021)
Abstract Background Synchronous oligometastatic non-small cell lung cancer (NSCLC) is generally characterised by the limited number of metastases at the time of diagnosis. Several clinical trials have shown that local ablative therapy (LAT) at all si
Externí odkaz:
https://doaj.org/article/39dfc6480ce2459281803dd7cfc8bd88
Autor:
Hiroaki Kanemura, MD, MPH, Hidetoshi Hayashi, MD, PhD, Shuta Tomida, PhD, Junko Tanizaki, MD, PhD, Shinichiro Suzuki, MD, PhD, Yusuke Kawanaka, MD, Asuka Tsuya, MD, Yasushi Fukuda, MD, Hiroyasu Kaneda, MD, PhD, Keita Kudo, MD, Takayuki Takahama, MD, PhD, Ryosuke Imai, MD, Koji Haratani, MD, PhD, Yasutaka Chiba, PhD, Tomoyuki Otani, MD, Akihiko Ito, MD, PhD, Kazuko Sakai, PhD, Kazuto Nishio, MD, PhD, Kazuhiko Nakagawa, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 8, Pp 100373- (2022)
Introduction: Despite a considerable benefit of adding immune checkpoint inhibitors (ICIs) to platinum-based chemotherapy for patients with extensive-stage SCLC (ES-SCLC), a durable response to ICIs occurs in only a small minority of such patients. M
Externí odkaz:
https://doaj.org/article/dbb20eead9094769a8713112200e34c2
Autor:
Yusuke Makutani, Hisato Kawakami, Takahiro Tsujikawa, Kanako Yoshimura, Yasutaka Chiba, Akihiko Ito, Junichiro Kawamura, Koji Haratani, Kazuhiko Nakagawa
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Matrix metalloproteinase 14 (MMP14) expression is implicated in progression of colorectal cancer, but its role in the tumor microenvironment (TME) has been unclear. The relevance of MMP14 to colorectal cancer progression was explored by analysis of t
Externí odkaz:
https://doaj.org/article/78158ca296c0489e8e6d30126d7284b8
Autor:
Osamu Nishiyama, Shigeki Shimizu, Koji Haratani, Kosuke Isomoto, Junko Tanizaki, Hidetoshi Hayashi, Ryo Yamazaki, Takashi Oomori, Yusaku Nishikawa, Akiko Sano, Kazuhiko Nakagawa, Yuji Tohda
Publikováno v:
BMC Pulmonary Medicine, Vol 21, Iss 1, Pp 1-8 (2021)
Abstract Background The utility of bronchoscopy for patients with suspected immune checkpoint inhibitor (ICI)-related pneumonitis is currently debatable. The purpose of this study was to examine the findings of bronchoalveolar lavage (BAL) analysis a
Externí odkaz:
https://doaj.org/article/305a527658b74ea1a42bff5dc704cf71
Autor:
Daichi Fujimoto, MD, Satoru Miura, MD, PhD, Kenichi Yoshimura, MD, PhD, Kazushige Wakuda, MD, Yuko Oya, MD, Koji Haratani, MD, PhD, Shoichi Itoh, MD, Takehiro Uemura, MD, PhD, Ryotaro Morinaga, MD, PhD, Takayuki Takahama, MD, PhD, Kazuhisa Nakashima, MD, Motoko Tachihara, MD, PhD, Go Saito, MD, Junko Tanizaki, MD, PhD, Kohei Otsubo, MD, PhD, Satoshi Ikeda, MD, Hirotaka Matsumoto, MD, Satoshi Hara, MD, Akito Hata, MD, Takeshi Masuda, MD, PhD, Nobuyuki Yamamoto, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 2, Pp 100265- (2022)
Introduction: The real-world effectiveness of combination treatment with cytotoxic chemotherapy and programmed cell death protein-1 or programmed death-ligand 1 inhibitor for NSCLC, especially for the elderly (aged ≥75 y) or those with poor perform
Externí odkaz:
https://doaj.org/article/334d6452dbd74ae68a67e6425d4802e8
Autor:
Hiroaki Akamatsu, MD, PhD, Shunsuke Teraoka, MD, Hidetoshi Hayashi, MD, PhD, Daichi Fujimoto, MD, Atsushi Hayata, MD, PhD, Koji Haratani, MD, PhD, Yuichi Ozawa, MD, PhD, Takeshi Yoshida, MD, PhD, Tsutomu Iwasa, MD, PhD, Toshio Shimokawa, MD, Keisuke Tomii, MD, PhD, Kazuhiko Nakagawa, MD, PhD, Nobuyuki Yamamoto, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 7, Pp 100184- (2021)
Introduction: In patients with relapsed SCLC, amrubicin (AMR) is the current standard treatment in Japan. Nevertheless, its efficacy is not satisfactory and prognosis is poor. Preclinical study suggested that anthracycline agent might induce immunoge
Externí odkaz:
https://doaj.org/article/772e441e14ed494d9dc68a90b6f84b8f
Publikováno v:
BMC Medicine, Vol 18, Iss 1, Pp 1-3 (2020)
Externí odkaz:
https://doaj.org/article/9cb4f75cf60f43a5856ee448a9aaecf0
Autor:
Yoshikane Nonagase, Masayuki Takeda, Koichi Azuma, Hidetoshi Hayashi, Koji Haratani, Kaoru Tanaka, Kimio Yonesaka, Hidenobu Ishii, Tomoaki Hoshino, Kazuhiko Nakagawa
Publikováno v:
Thoracic Cancer, Vol 10, Iss 10, Pp 1928-1935 (2019)
Background Non‐small cell lung cancer (NSCLC) positive for activating mutations of the epidermal growth factor receptor (EGFR) gene is initially sensitive to EGFR‐tyrosine kinase inhibitors (TKIs) but eventually develops resistance to these drugs
Externí odkaz:
https://doaj.org/article/9c68df9741e046f8b31dc2fc7b022f3c